CurveBeam AI has reported a record quarter for HiRise™ device purchase orders, driven by a strategic expansion with Stryker in Australia and New Zealand. The company also advanced its FDA regulatory pathway for its BMD module, setting sights on mid-2025 submission.
FBR Limited has received a substantial A$6.3 million R&D tax incentive rebate from the Australian Taxation Office, strengthening its financial position as it wraps up its US Demonstration Program with additional funding from CRH Ventures.